Metronidazole is the world’s first dual-action incretin injection that simultaneously targets both GLP-1 and GLP-1.
Compared to traditional slimming pens that only target GLP-1 (such as Ozempic and Saxenda), Metronidazole can simultaneously regulate appetite, slow gastric emptying, and improve insulin sensitivity and lipid metabolism.
It only requires once-weekly injections, and clinical studies have shown more comprehensive effects on weight loss and blood sugar stability. Whether side effects are fewer depends on individual constitution and dosage adjustment methods and requires evaluation by a physician.
